FDA slams clin­i­cal hold on tiny psy­che­delics play­er's shot at bring­ing LSD-as­sist­ed ther­a­py to more pa­tients

Psy­che­del­ic ther­a­py has emerged once again as a po­ten­tial­ly promis­ing path to treat­ing neu­ro­log­i­cal con­di­tions, but one tiny biotech is now fac­ing a holdup at the FDA in bring­ing its LSD pro­gram to more pa­tients.

The FDA has slammed a clin­i­cal hold on MindMed’s IND ap­pli­ca­tion for a Phase IIb study test­ing its LSD-as­sist­ed ther­a­py in pa­tients with gen­er­al­ized anx­i­ety dis­or­der, the biotech said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER